Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Trading Down 3.1 %

Evogene stock opened at $1.39 on Tuesday. The company has a market cap of $7.44 million, a P/E ratio of -0.31 and a beta of 1.28. Evogene has a 1-year low of $1.20 and a 1-year high of $9.00. The company has a fifty day simple moving average of $1.51 and a 200 day simple moving average of $1.92.

Evogene (NASDAQ:EVGN) last released its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. The business had revenue of $1.61 million during the quarter, compared to the consensus estimate of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter last year, the firm earned ($1.30) earnings per share.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.